perspective therapeutics inc - CATX
CATX
Close Chg Chg %
2.75 0.06 2.18%
Closed Market
2.81
+0.06 (2.18%)
Volume: 1.23M
Last Updated:
Jan 2, 2026, 3:59 PM EDT
Company Overview: perspective therapeutics inc - CATX
CATX Key Data
| Open $2.75 | Day Range 2.71 - 2.82 |
| 52 Week Range 1.60 - 5.39 | Market Cap $204.43M |
| Shares Outstanding 74.34M | Public Float 61.65M |
| Beta 1.19 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.46 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.33M |
CATX Performance
| 1 Week | -3.12% | ||
| 1 Month | 16.25% | ||
| 3 Months | -23.35% | ||
| 1 Year | -20.51% | ||
| 5 Years | -38.00% |
CATX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About perspective therapeutics inc - CATX
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
CATX At a Glance
Perspective Therapeutics, Inc.
2401 Elliott Avenue
Seattle, Washington 98121
| Phone | 1-206-676-0900 | Revenue | 1.45M | |
| Industry | Medical Specialties | Net Income | -79,279,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 1.395% | |
| Fiscal Year-end | 12 / 2025 | Employees | 140 | |
| View SEC Filings |
CATX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 141.345 |
| Price to Book Ratio | 0.776 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.269 |
| Enterprise Value to Sales | -11.925 |
| Total Debt to Enterprise Value | -0.234 |
CATX Efficiency
| Revenue/Employee | 10,385.714 |
| Income Per Employee | -566,278.571 |
| Receivables Turnover | 0.98 |
| Total Asset Turnover | 0.006 |
CATX Liquidity
| Current Ratio | 12.68 |
| Quick Ratio | 12.68 |
| Cash Ratio | 12.447 |
CATX Profitability
| Gross Margin | -58.597 |
| Operating Margin | -4,594.017 |
| Pretax Margin | -5,531.431 |
| Net Margin | -5,452.476 |
| Return on Assets | -34.29 |
| Return on Equity | -42.821 |
| Return on Total Capital | -26.577 |
| Return on Invested Capital | -42.186 |
CATX Capital Structure
| Total Debt to Total Equity | 1.397 |
| Total Debt to Total Capital | 1.378 |
| Total Debt to Total Assets | 1.16 |
| Long-Term Debt to Equity | 1.05 |
| Long-Term Debt to Total Capital | 1.036 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Perspective Therapeutics Inc - CATX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 10.05M | 10.79M | 1.43M | 1.45M | |
Sales Growth
| +3.85% | +7.38% | -86.72% | +1.39% | |
Cost of Goods Sold (COGS) incl D&A
| 4.93M | 6.18M | 1.02M | 2.31M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 221.00K | 325.00K | 1.02M | 2.31M | |
Depreciation
| 184.00K | 284.00K | 981.00K | 2.30M | |
Amortization of Intangibles
| 37.00K | 41.00K | 40.00K | 7.00K | |
COGS Growth
| +8.25% | +25.28% | -83.48% | +125.86% | |
Gross Income
| 5.12M | 4.62M | 413.00K | (852.00K) | |
Gross Income Growth
| -0.06% | -9.86% | -91.05% | -306.30% | |
Gross Profit Margin
| +50.94% | +42.76% | +28.80% | -58.60% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 8.56M | 12.01M | 41.35M | 65.94M | |
Research & Development
| 1.43M | 2.58M | 20.33M | 39.33M | |
Other SG&A
| 7.13M | 9.43M | 21.02M | 26.61M | |
SGA Growth
| -1.33% | +40.30% | +244.42% | +59.46% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 24.06M | - |
EBIT after Unusual Expense
| (3.44M) | (7.39M) | (40.94M) | (90.86M) | |
Non Operating Income/Expense
| 50.00K | 119.00K | 919.00K | 10.48M | |
Non-Operating Interest Income
| 59.00K | 119.00K | 934.00K | 10.52M | |
Equity in Earnings of Affiliates
| - | - | (17.00K) | (8.00K) | - |
Interest Expense
| - | - | 84.00K | 48.00K | - |
Interest Expense Growth
| - | - | - | -42.86% | - |
Gross Interest Expense
| - | - | 84.00K | 48.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (3.39M) | (7.27M) | (40.11M) | (80.43M) | |
Pretax Income Growth
| +1.71% | -114.70% | -451.51% | -100.54% | |
Pretax Margin
| -33.69% | -67.36% | -2,796.79% | -5,531.43% | |
Income Tax
| - | - | (2.65M) | (2.10M) | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | (2.65M) | (2.10M) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | (17.00K) | (8.00K) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (3.39M) | (7.27M) | (37.45M) | (78.33M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (3.39M) | (7.27M) | (37.45M) | (78.33M) | |
Net Income Growth
| +1.71% | -114.70% | -415.06% | -109.13% | |
Net Margin Growth
| -33.69% | -67.36% | -2,611.92% | -5,387.21% | |
Extraordinaries & Discontinued Operations
| - | - | (9.05M) | (949.00K) | - |
Discontinued Operations
| - | - | (9.05M) | (949.00K) | - |
Net Income After Extraordinaries
| (3.39M) | (7.27M) | (46.51M) | (79.28M) | |
Preferred Dividends
| - | - | - | 3.00K | - |
Net Income Available to Common
| (3.39M) | (7.27M) | (46.51M) | (79.28M) | |
EPS (Basic)
| -0.3265 | -0.5122 | -1.7377 | -1.2306 | |
EPS (Basic) Growth
| +36.16% | -56.88% | -239.26% | +29.18% | |
Basic Shares Outstanding
| 10.38M | 14.20M | 26.76M | 64.42M | |
EPS (Diluted)
| -0.3265 | -0.5122 | -1.7377 | -1.2306 | |
EPS (Diluted) Growth
| +36.16% | -56.88% | -239.26% | +29.18% | |
Diluted Shares Outstanding
| 10.38M | 14.20M | 26.76M | 64.42M | |
EBITDA
| (3.22M) | (7.07M) | (39.92M) | (64.49M) | |
EBITDA Growth
| +3.45% | -119.71% | -464.96% | -61.55% | |
EBITDA Margin
| -31.99% | -65.46% | -2,783.82% | -4,435.42% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 12.308 | |
| Number of Ratings | 14 | Current Quarters Estimate | -0.382 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.33 | |
| Last Quarter’s Earnings | -0.37 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.226 | Next Fiscal Year Estimate | -1.253 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 12 | 9 |
| Mean Estimate | -0.38 | -0.36 | -1.33 | -1.25 |
| High Estimates | -0.24 | -0.26 | -0.99 | -0.66 |
| Low Estimate | -0.50 | -0.45 | -1.98 | -2.10 |
| Coefficient of Variance | -23.58 | -18.72 | -23.71 | -34.13 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 14 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Perspective Therapeutics Inc - CATX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Perspective Therapeutics Inc - CATX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Lori A. Woods Director | 183,460 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.13 per share | 390,769.80 |
| Apr 2, 2025 | Robert F. Williamson Director | 70,837 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.27 per share | 160,799.99 |
| Apr 2, 2025 | Robert F. Williamson Director | 108,982 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.14 per share | 233,221.48 |
| Apr 2, 2025 | Johan M. Spoor Chief Executive Officer; Director | 59,383 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.24 per share | 133,017.92 |
| Apr 2, 2025 | Johan M. Spoor Chief Executive Officer; Director | 4,650 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.21 per share | 10,276.50 |
| Apr 2, 2025 | Juan Graham Chief Financial Officer | 35,354 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.25 per share | 79,546.50 |
| Mar 6, 2025 | Heidi Henson Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Jonathan R. Hunt Chief Accounting Officer | 75,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Frank M. Morich Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Markus Puhlmann Chief Medical Officer | 165,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |